0001022079-14-000002.txt : 20140114 0001022079-14-000002.hdr.sgml : 20140114 20140114164251 ACCESSION NUMBER: 0001022079-14-000002 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20140110 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20140114 DATE AS OF CHANGE: 20140114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 14527760 BUSINESS ADDRESS: STREET 1: 3 GIRALDA FARMS CITY: MADISON STATE: NJ ZIP: 07940 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 3 GIRALDA FARMS CITY: MADISON STATE: NJ ZIP: 07940 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 8-K 1 dgx0110148-k.htm 8-K DGX 011014 8-K


SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K
____________________________

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): January 10, 2014
____________________________

Quest Diagnostics Incorporated
(Exact Name of Registrant as Specified in Its Charter)
___________________________

Delaware
(State or other jurisdiction of Incorporation)
 
 
 
001-12215
 
16-1387862
(Commission File Number)
 
(I.R.S. Employer Identification No.)
 
 
 
Three Giralda Farms
Madison, NJ 07940
 
07940
(Address of principal executive offices)
 
(Zip Code)
 
 
 
(973) 520-2700
(Registrant’s telephone number, including area code)
 
 
 
___________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction a.2. below):
 [ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the exchange Act
(17 CFR 240.13e-4(c))
 
 






Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) On January 10, 2014, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”) increased its size from 9 to 10 directors, and increased the number of directors in the class of directors whose term expires at the Company’s 2014 Annual Meeting of Stockholders from 3 to 4. After considering the recommendation of the Board's Governance Committee, the Board elected Timothy L. Main, Chairman of Jabil Circuit, Inc. to fill the resulting vacancy.

The Board determined that Mr. Main is an independent director pursuant to the New York Stock Exchange listing standards and the Company’s independence guidelines, as set forth in its corporate governance principles.

The Board appointed Mr. Main to its Audit and Finance Committee, which was increased in size from 4 to 5 members.

Mr. Main will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation practices described in the Company’s proxy statement for its annual meeting of stockholders, filed April 11, 2013. As part of that compensation, Mr. Main received a one-time grant of 2,037 options and 658 restricted stock units upon becoming a member of the Company’s Board.

A copy of the Company’s press release announcing the election is attached hereto as exhibit 99.1 and is hereby incorporated by reference.


Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

99.1 Press release dated January 13, 2014.


Signature
    
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.


January 13, 2014


QUEST DIAGNOSTICS INCORPORATED



By:    /s/ William J. O’Shaughnessy, Jr.
William J. O’Shaughnessy, Jr.
Deputy General Counsel and Secretary



EX-99.1 2 exhibit991_011014.htm PRESS RELEASE Exhibit 99.1_011014


Exhibit 99.1
News From Quest Diagnostics
Quest Diagnostics Contacts:
Dan Haemmerle (Investors): 973-520-2900
Wendy Bost (Media): 973-520-2800


Quest Diagnostics Adds Timothy L. Main to Board of Directors

MADISON, N.J., January 13, 2014 - Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Timothy L. Main to serve as a director, effective immediately. Including Mr. Main, the Board has 10 members.


Tim Main currently serves as Chairman of the Board of Directors for Jabil Circuit, Inc. (NYSE: JBL), an electronic product solutions company providing comprehensive electronics design, manufacturing and management services to global electronics and technology companies. Mr. Main joined Jabil in April 1987 and served in a number of operations and business development roles before being appointed Chief Executive Officer in September 2000, a role he held until 2013. As CEO, Mr. Main led Jabil’s growth strategy, increasing annual revenues nearly fivefold to reach $17 billion in 2012, and expanding in Asia and other emerging markets.  

“Tim has an exceptional record of generating business growth and shareholder value in a competitive, complex global market,” said Steve Rusckowski, President and CEO, Quest Diagnostics. “This experience, coupled with his deep understanding of operations and supply chain management, will enable him to share a fresh, compelling perspective on Quest as we execute our strategy to restore growth, drive operational excellence and deliver disciplined capital deployment.”

Daniel C. Stanzione, Ph.D., Chairman of the Board of Directors of Quest Diagnostics, added: “As the chairman and former CEO of a large multinational with an operations-intensive business, Tim Main brings expertise in strategy, operations, and corporate governance that will be helpful to our company. We are pleased to welcome him to the Quest Board.”

Mr. Main earned a B.S. degree from Michigan State University and Master of International Management degree from the American Graduate School of International Management (Thunderbird).

About Quest Diagnostics
Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic information services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at QuestDiagnostics.com. Follow us at Facebook.com/QuestDiagnostics and Twitter.com/QuestDX.
 
Quest, Quest Diagnostics, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks are the property of their respective owners.